Navigation Links
Immunosyn Corporation Files 10-Q
Date:5/16/2008

LA JOLLA, Calif., May 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending March 31, 2008.

For the quarter ended March 31, 2008, the company incurred $175,632.00 in general and administrative expenses and $13,393.00 in interest expense which was funded from advances by affiliates of $179,798.00, accounts payable of $32,249.00 and accrued expenses of $12,151.00. As a result, the company had a Net Loss of $189,025.00 for the first quarter of 2008. During the same period in 2007, the company incurred $162,714.00 in general and administrative expenses and interest expense of $3,714.00 and had a Net Loss of $166,428.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated the advances from affiliates," noted Stephen Ferrone, Immunosyn's CEO. "In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating di
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
3. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
4. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
5. Immunosyn Corporation Names G. David Criner as CFO
6. Immunosyn Corporation to Present at FSX
7. CorVel Corporation Announces Earnings Release Webcast
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
10. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
(Date:7/29/2014)... 2014 White papers by Clinovo ... based eClinical technologies, have been published by leading pharmaceutical ... a long line of white papers by Clinovo to ... Science Leader, Pharmaceutical Online, and OpenHealthNews. , At the ... by CTO Marc Desgrousilliers, 'The Five Essentials of ...
(Date:7/28/2014)... materials using light, developed by researchers at the University ... often considered the realm of science fiction, such as ... starships won,t be a reality for quite some time, ... with building blocks a few billionths of a metre ... light flies through them, and works on large chunks ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3Building 'invisible' materials with light 2
... 2012  Avaxia Biologics, Inc., a privately-held biotech company using ... for the treatment of gastrointestinal diseases, announced today that ... Officer of Arisaph Pharmaceuticals, Inc. to its Board of ... has agreed to serve on our Board," said Dr. ...
... Europe,s premier biotech conference continues to grow and see ... network which provides comprehensive support for bioscience businesses in ... announced the results of the sixth annual BioTrinity Biopartnering ... at Newbury Racecourse, UK, BioTrinity is now firmly established ...
... IRVINE, Calif., April 25, 2012 Aviir Diagnostic ... a contractual agreement with MultiPlan, Inc. for ancillary ... in the MultiPlan, PHCS and PHCS Savility Networks. ... cardiologists and scientists from the Stanford University School ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Another Record Year for BioTrinity 2Another Record Year for BioTrinity 3Aviir Laboratories Announce National Agreement With MultiPlan 2
(Date:7/29/2014)... different types of cell, including sperm, bacteria and ... flagella. These protrusions, about one-hundredth of a millimetre ... through fluid. Similar, shorter structures called cilia are ... they perform roles such as moving liquids over ... remarkably versatile: they transport mucus and expel pathogens ...
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
... provide the ideal petri dish for cultivating bioscience with ... so, given the opportunity to translate public funding into ... by UCSF researchers. In an analysis published Oct. ... at the California Institute for Quantitative Biosciences (QB3) assessed ...
... Risks of Overfishing," published today in the journal ... the Institute for Ocean Conservation Science and professor at ... According to Dr. Pikitch, current and recent studies demonstrate ... management, in which fishing is restricted to those places ...
Cached Biology News:New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2Academia should fulfill social contract by supporting bioscience startups, case study says 2Academia should fulfill social contract by supporting bioscience startups, case study says 3Traditional fisheries management approach jeopardizes marine ecosystems worldwide 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
... are multi-functional mixing devices. Stepping motors device ... solid, heavy-duty durable shaker to provide a ... vortexing in nature. Regulated action scale for ... display to control time, continuous time, action ...
Biology Products: